{
    "root": "2ef8a999-c2db-ef91-8a61-94663c09d584",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "JAIMIESS",
    "value": "20241125",
    "ingredients": [],
    "indications": "Jaimiess is indicated for use by females of reproductive potential to prevent pregnancy.",
    "contraindications": "Take one tablet daily by mouth at the same time every day for 91 days in the order directed on the blister pack. ( 2 )",
    "warningsAndPrecautions": "How Supplied\n                  \n                  Jaimiess (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP) is available in an Extended-Cycle Tablet Blister Pack, each pouch contains 91 tablets. Each Extended-Cycle Tablet Blister Pack contains a 13-week supply of tablets: 84 white to off-white tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg ethinyl estradiol, and 7 light peach tablets each containing 0.01 mg of ethinyl estradiol. The white to off-white tablets are round, biconvex tablets debossed with 202 on one side and plain on the other side. The light peach tablets are round, biconvex tablets debossed with 222 on one side and plain on the other side.\n                  NDC 70700-206-93 Carton containing 2 Extended-Cycle Tablet Blister Packs\n                  \n                     Storage and Handling\n                  \n                  \n                     Store at 20째 to 25째C (68째 to 77째 F) [See USP Controlled Room Temperature].",
    "adverseReactions": "Jaimiess is contraindicated in females who are known to have or develop the following conditions:\n                  \n                     \n                        A high risk of arterial or venous thrombotic diseases. Examples include females who are known to:\n                        \n                           \n                              -Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions (5.1)].\n                           \n                              -Have current or history of deep vein thrombosis or pulmonary embolism [see Warnings and Precautions (5.1)].\n                           \n                              \n                                 -Have cerebrovascular disease [see Warnings and Precautions (5.1)].\n                           \n                           \n                              -Have coronary artery disease [see Warnings and Precautions (5.1)].\n                           \n                              -Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1)].\n                           \n                              -Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1)].\n                           \n                              -Have uncontrolled hypertension or hypertension with vascular disease [see Warnings and Precautions (5.3)].\n                           \n                              \n                                 -Have diabetes mellitus and are over age 35, diabetes mellitus with hypertension or with vascular disease or other end-organ damage, or diabetes mellitus of > 20 years duration [see Warnings and Precautions (5.7)].\n                           \n                           \n                              \n                                 -Have headaches with focal neurological symptoms, migraine headaches with aura, or over age 35 with any migraine headaches [see Warnings and Precautions (5.8)].\n                           \n                        \n                     \n                     \n                        Current diagnosis of, or history of, breast cancer, which may be hormone sensitive [see Warnings and Precautions (5.11)].\n                        \n                     \n                     \n                        Liver tumors, acute viral hepatitis, or severe (decompensated) cirrhosis [see Warnings and Precautions (5.2) and Use in Specific Populations (8.6)]. \n                        \n                     \n                     \n                        Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.9)].\n                        \n                     \n                     \n                        Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see Warnings and Precautions (5.4)]."
}